Kathryn Zoon - Emergent Biosolutions Independent Director
| EBS Stock | USD 7.27 0.06 0.83% |
Director
Dr. Kathryn C. Zoon, Ph.D., is Independent Director of the Company. Dr. Zoon is currently NIAIDNIH Scientist Emeritus, a position she has held since August 2016. From April 2016 to June 2016, she was Interim Director of the new NIH Office of Research Support and Compliance where she developed and established the new office and recruited key individuals to continue its future operations. She was also Chief of the Cytokine Biology Section in the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH until July 2016, where she conducted research on the structure and function of human interferon alphas and developed a new cell therapy using IFNs and autologous monocytes which she is still collaborating with the National Cancer Institute to start a clinical trial for ovarian cancer. She was previously the Director of the Division of Intramural Research at NIAID from 2006 August 2015 and was the Deputy Director for Planning and Development of the Division of Intramural Research at NIAID, 20042006. Dr. Zoon served as the Principal Deputy Director of the Center for Cancer Research at the National Cancer Institute, 20032004. She served as the Director of the Center for Biologics Evaluation and Research, Food and Drug Administration, and was a member of the NIH Scientific Directors from 1992 to 2015 since 2016.
| Age | 71 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 400 Professional Drive, Gaithersburg, MD, United States, 20879 |
| Phone | 240 631 3200 |
| Web | https://www.emergentbiosolutions.com |
Kathryn Zoon Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kathryn Zoon against Emergent Biosolutions stock is an integral part of due diligence when investing in Emergent Biosolutions. Kathryn Zoon insider activity provides valuable insight into whether Emergent Biosolutions is net buyers or sellers over its current business cycle. Note, Emergent Biosolutions insiders must abide by specific rules, including filing SEC forms every time they buy or sell Emergent Biosolutions'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kathryn Zoon over six months ago Disposition of 10000 shares by Kathryn Zoon of Emergent Biosolutions at 6.11 subject to Rule 16b-3 | ||
Kathryn Zoon over six months ago Disposition of 1830 shares by Kathryn Zoon of Emergent Biosolutions at 4.61 subject to Rule 16b-3 |
Emergent Biosolutions Management Efficiency
The company has Return on Asset of (0.0422) % which means that on every $100 spent on assets, it lost $0.0422. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3464) %, meaning that it generated no profit with money invested by stockholders. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.66 in 2025. Return On Capital Employed is likely to gain to -0.68 in 2025. At this time, Emergent Biosolutions' Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 231 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 799.2 M in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Byom | Prestige Brand Holdings | 66 | |
| Frank DAmelio | Zoetis Inc | 63 | |
| William Steere | Zoetis Inc | 83 | |
| Sarah Kavanagh | Bausch Health Companies | 63 | |
| Willie Reed | Zoetis Inc | 65 | |
| James Jenness | Prestige Brand Holdings | 73 | |
| Katharyn Field | Akanda Corp | 41 | |
| Amy Wechsler | Bausch Health Companies | 50 | |
| Natale Ricciardi | Prestige Brand Holdings | 71 | |
| Andrew Eschenbach | Bausch Health Companies | 78 | |
| Gary Costley | Prestige Brand Holdings | 55 | |
| Richard Schutter | Bausch Health Companies | 79 | |
| Russel Robertson | Bausch Health Companies | 72 | |
| Celeste Clark | Prestige Brand Holdings | 67 | |
| Gregory Norden | Zoetis Inc | 62 | |
| Linda Rhodes | Zoetis Inc | 70 | |
| Argeris Karabelas | Bausch Health Companies | 66 | |
| Dawn Zier | Prestige Brand Holdings | 55 | |
| Sheila Hopkins | Prestige Brand Holdings | 64 | |
| Thomas Ross | Bausch Health Companies | 69 | |
| Robert Power | Bausch Health Companies | 63 | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0422 |
Emergent Biosolutions Leadership Team
Elected by the shareholders, the Emergent Biosolutions' board of directors comprises two types of representatives: Emergent Biosolutions inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Emergent. The board's role is to monitor Emergent Biosolutions' management team and ensure that shareholders' interests are well served. Emergent Biosolutions' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Emergent Biosolutions' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kelly Warfield, Senior Development | ||
| Sean Kirk, Executive Vice President - Manufacturing and Technical Operations | ||
| William Hartzel, Senior Bioservices | ||
| Robert Burrows, IR Contact Officer | ||
| Stephanie Duatschek, Chief VP | ||
| Sue Bailey, Independent Director | ||
| Jerome Hauer, Independent Director | ||
| Haywood Miller, Interim Officer | ||
| Kathryn Zoon, Independent Director | ||
| Seamus Mulligan, Director | ||
| George Joulwan, Independent Director | ||
| Karen Smith, Executive Vice President Chief Medical Officer | ||
| Paul Williams, Senior Business | ||
| Keith Katkin, Independent Director | ||
| Simon MD, Chief Development | ||
| Jessica Perl, Corporate Counsel | ||
| Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
| Richard MBA, CFO VP | ||
| Jennifer Fox, Executive Vice President - External Affairs, General Counsel, Corporate Secretary | ||
| Katherine Strei, Executive Vice President - Human Resources and Communications, Chief Human Resources Officer | ||
| Michelle Pepin, Senior Officer | ||
| Fuad ElHibri, Executive Chairman of the Board | ||
| Coleen Glessner, Executive Compliance | ||
| Lynn Kieffer, VP Communications | ||
| Joseph Papa, CEO President | ||
| Marvin White, Director | ||
| Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
| Robert Sr, Pres CEO | ||
| Adam Havey, Executive VP and President of Biodefense Division | ||
| Louis Sullivan, Independent Director | ||
| Ronald Richard, Lead Independent Director | ||
| Zsolt Harsanyi, Non-Executive Independent Chairman of the Board | ||
| Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
Emergent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Emergent Biosolutions a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0422 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 903.37 M | ||||
| Shares Outstanding | 54.18 M | ||||
| Shares Owned By Insiders | 2.15 % | ||||
| Shares Owned By Institutions | 57.78 % | ||||
| Number Of Shares Shorted | 6.95 M | ||||
| Price To Earning | 1.67 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.